Open company graph database — free web & API
Login

Eisai Pharmaceuticals Single Person LLC

Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
10,917
Related companies
29
§01

Basic information

BASIC
Head office
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Chief executive
Haruo Naito
Capital
44,986 JPY
Employees (non-consolidated)
2,998 people
Employees (consolidated)
10,917 people
Start date
1941-12-06
End date
§02

Websites

1 DOMAINS
§03

Business

4
Research and developmentManufactureSaleImport and export of pharmaceuticals
§04

Related companies

29 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Eisai Korea Inc.
Group Customer
Eisai (Hong Kong) Co., Ltd.
Group
Eisai (Liaoning) Pharmaceutical Co., Ltd.
Group
Eisai (Suzhou) Trading Co., Ltd.
Group
Eisai (Thailand) Marketing Co., Ltd.
Group
Eisai Australia Pty. Ltd.
Group
Eisai China Inc.
Group
Eisai Clinical Research Singapore Pte. Ltd.
Group
Eisai Israel Ltd.
Group
Eisai New Zealand Ltd.
Group
Eisai Pharmaceuticals Africa (Pty) Ltd
Group
Eisai Vietnam Co., Ltd.
Group
Eisai (Malaysia) Sdn. Bhd.
Group
Eisai (Singapore) Pte. Ltd.
Group
Eisai GesmbH
Group
Limited Liability Company Eisai
Group
PT Eisai Indonesia
Group
SampleNet Corporation
Group
EA Pharma Co., Ltd.
Group
HI-Eisai Pharmaceutical, Inc.
Group Customer
Wei Cai Pharmaceuticals Co., Ltd.
Group
Bogor Factory
Group
Eisai AB
Group
Eisai China Inc.
Group
Eisai Farmacêutica, Unipessoal Lda.
Group
Eisai Pharmaceuticals India Pvt. Ltd.
Group
Eisai SA/NV
Group
Suzhou Factory
Group
Unlimit Health Limited
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

167 EVENTS

Eisai's founder, Toyoji Naito, is born on August 15 in Ito, a village in Fukui, central Japan. He is the sixth child and third son of Kikuji Naito and his wife, Fuji.Sources

Toyoji leaves his village at age 15, heading west to find employment in Osaka.Sources

Toyoji is employed at Winkel Shokai in nearby Kobe, a port city in Hyogo. Meanwhile, he takes night courses in foreign languages and bookkeeping.Sources

Toyoji leaves Winkel Shokai on being drafted into the Japanese Imperial Guard.Sources

After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe.Sources

World War I begins.Sources

Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd. (now part of the Mitsubishi Tanabe Pharma Corporation).Sources

Toyoji embarks on a seven-month business tour of India and Southeast Asia.Sources

World War I ends.Sources

Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil : Castalol : and analgesic cream : Salomethyl : .Sources

The Great Kanto Earthquake strikes. Tanabe Motosaburo Store Co., Ltd. falls on hard times, including when its main store in Tokyo burns down in the aftermath of the quake.Sources

Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, : Animasa : . A Japanese word Toyoji coins for 'high blood pressure' in his : Animasa : ad campaign enters the Japanese lexicon and remains a general medical term today.Sources

A : Salomethyl : newspaper ad created by Toyoji wins Best Advertisement Award in the first award ceremony of Japan's Society for the Promotion of Newspaper Advertising. Tanabe Motosaburo Store Co., Ltd. launches vitamin A product : Haliva : (halibut liver oil tablets).Sources

Sakuragaoka Laboratory Co., Ltd. is established as a limited partnership in Tokyo.Sources

Toyoji travels abroad to observe pharmaceutical industries in Europe and the United States.Sources

Sakuragaoka Laboratory Co., Ltd. launches vitamin E product : Juvela : through Tanabe Motosaburo Store Co., Ltd. Its chocolate-brown coating, 'hard outside, soft inside' pellets and stylish packaging garners much attention at the time. Juvela : becomes the laboratory's first success. Sakuragaoka Laboratory Co., Ltd. launches : Sampon : , Japan's first sanitary tampon, through Tanabe Motosaburo Store Co., Ltd.Sources

World War II begins.Sources

Nihon Eisai Co., Ltd., Eisai Co., Ltd.'s immediate predecessor, is established in Saitama, eastern Japan.Sources

Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merge under the name Nihon Eisai Co., Ltd.Sources

World War II ends.Sources

Nihon Eisai Co., Ltd.'s contraceptive suppository : Sampoon : , researched and developed during Japan's postwar baby boom, receives official approval from the Japanese government.Sources

Nihon Eisai Co., Ltd. launches cardiotonic : Neophyllin : in Japan.Sources

Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product : Chocola BB Tablets : in Japan.Sources

Nihon Eisai Co., Ltd. launches motion sickness remedy : Travelmin : in Japan.Sources

The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today.Sources

Eisai rolls out its first three-year mid-term plan.Sources

Eisai's Head Office building is completed in Tokyo.Sources

Eisai opens its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan.Sources

Eisai is publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges.Sources

Gastrointestinal remedies : Saclon : and : Saclon Tablets : , recognizable for their distinct green hue even today, are launched in Japan.Sources

Toyoji Naito receives the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan.Sources

The Kawashima Plant is completed in Gifu, central Japan.Sources

Kawashima Plant opening ceremony.Sources

Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president.Sources

A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.Sources

Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.Sources

PT Eisai Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia.Sources

Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.Sources

Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.Sources

Eisai (Malaysia) Ltd. is established as a pharmaceutical sales subsidiary in Malaysia.Sources

Hi-Eisai Pharmaceutical Inc. is established as a pharmaceutical sales subsidiary in the Philippines.Sources

Metabolic cardiotonic : Neuquinon : is launched in Japan.Sources

Naturally derived vitamin E product : Juvelux : is launched in Japan.Sources

Eisai's founder Toyoji Naito passes away at age 89.Sources

Peripheral neuropathy treatment : Methycobal : is launched in Japan.Sources

Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore.Sources

Eisai U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States.Sources

The Misato Plant commences pharmaceutical manufacturing in Saitama.Sources

Large-scale automated sugar-coating equipment (pan diameter of up to 170 cm) at the Misato PlantSources

The Tsukuba Research Laboratories open in Ibaraki, eastern Japan.Sources

Eisai Chemical Co., Ltd. (now Eisai's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs).Sources

Gastritis and gastric ulcer treatment : Selbex : is launched in Japan.Sources

Eisai has supported of the Health and Medical Care Contributions Awards, which are presented to healthcare professionals who have contributed significantly to improving access to healthcare in difficult-to-reach areas from 1987 to 2015.Sources

Eisai rolls out its first five-year mid-term plan.Sources

Eisai Research Institute of Boston, Inc. (now the Boston Research Institute) is established as a discovery research subsidiary in Massachusetts, the United States.Sources

President Yuji Naito steps down from office and assumes the role of chairman; Vice President Haruo Naito is appointed president of Eisai.Sources

Eisai America, Inc. is established as a clinical research subsidiary in New Jersey, the United States.Sources

Eisai Europe Ltd. is established as a clinical research subsidiary in London, the United Kingdom.Sources

Eisai Machinery GmbH is established as a pharmaceutical machinery sales subsidiary in Cologne, former West Germany.Sources

Eisai (Thailand) Marketing Co., Ltd. is established as a pharmaceutical sales subsidiary in Bangkok, Thailand.Sources

Haruo Naito announces Eisai's “Commitment to Innovation.”Sources

Eisai London Research Laboratories, Ltd. is established as a discovery research subsidiary attached to University College London in the United Kingdom.Sources

Eisai Hong Kong Co., Ltd. is established as a pharmaceutical sales subsidiary in Hong Kong.Sources

The Beijing Representative Office is established in Beijing, China.Sources

Shenyang Eisai Pharmaceutical Co., Ltd. is established as a Chinese–foreign contractual joint venture in pharmaceutical manufacturing and sales in Shenyang, China.Sources

Eisai celebrates its 50th anniversary.Sources

Eisai adopts its current Corporate Mission and Corporate Objective.Sources

Eisai Corporation of North America is established as a holding company in New Jersey, the United States.Sources

Eisai London Research Laboratories, Ltd. is completed in the United Kingdom to form an Eisai Group multipolar R&D network spanning Japan, America and Europe.Sources

Eisai London Research Laboratories opening ceremony in 1993 attended by the United Kingdom's Princess Royal, Princess Anne.Sources

Eisai Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the United States.Sources

Eisai Ltd. is established as a pharmaceutical sales subsidiary in London, the United Kingdom.Sources

Eisai Deutschland GmbH is established as a pharmaceutical sales subsidiary in Frankfurt, Germany.Sources

Eisai S.A. is established as a pharmaceutical sales subsidiary in Paris, France.Sources

Eisai Suzhou Pharmaceutical Co., Ltd. is established as a pharmaceutical manufacturing and sales subsidiary in Jiangsu, China.Sources

Elmed Eisai Co., Ltd. is established as a generic drug sales subsidiary in Tokyo.Sources

KAN Research Institute, Inc. (now Kobe Research Laboratories, in Hyogo) is established as a life science exploratory research subsidiary in Osaka, Japan.Sources

Eisai Korea Inc. is established as a pharmaceutical sales subsidiary in Seoul, South Korea.Sources

Eisai Inc. North Carolina Plant is established as a pharmaceutical manufacturing and formulation R&D facility at Research Triangle Park in North Carolina, the United States.Sources

Anti-Alzheimer's agent Aricept is launched in the United States, the United Kingdom and Germany.Sources

Proton-pump inhibitor Pariet is launched in Japan.Sources

Aricept is launched in France.Sources

Pariet is launched in Germany and the United Kingdom.Sources

Pariet is launched under the brand name AcipHex in the United States.Sources

Aricept is launched in Japan.Sources

Eisai Farmacéutica S.A. is established as a pharmaceutical sales and marketing subsidiary in Madrid, Spain.Sources

Eisai Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.Sources

Eisai adopts the “Company with Committees” system.Sources

Eisai Europe Ltd. is established as a European regional headquarters (holding company) in London, the United Kingdom.Sources

Eisai Pharmaceuticals India Pvt. Ltd. is established as a pharmaceutical sales subsidiary in Mumbai, India.Sources

Eisai Ltd. is established as a pharmaceutical sales subsidiary in Milan, Italy.Sources

Eisai Pharma AG is established as a pharmaceutical sales subsidiary in Zurich, Switzerland.Sources

The Corporate Mission is added to the Eisai Articles of Incorporation.Sources

Eisai AB is established as a pharmaceutical sales subsidiary in Stockholm, Sweden.Sources

Honorary chairman and Eisai's second president Yuji Naito passes away at age 85.Sources

Eisai Australia Pty. Ltd. is established as a pharmaceutical sales subsidiary in Sydney, Australia.Sources

Eisai rolls out its fifth mid-term plan, the “Dramatic Leap Plan.”Sources

Eisai (Singapore) Pte. Ltd. is established as a pharmaceutical sales subsidiary in Singapore.Sources

Eisai Clinical Research Singapore Pte. Ltd. is established as a clinical research subsidiary in Singapore.Sources

Eisai acquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States.Sources

EF-Eisai Farmacêutica, Unipessoal Lda. is established as a pharmaceutical sales subsidiary in Lisbon, Portugal.Sources

Eisai Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom.Sources

Eisai acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States.Sources

Eisai Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India.Sources

Eisai SA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium.Sources

Eisai acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States.Sources

Eisai Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery.Sources

Rheumatoid arthritis treatment Humira is launched in Japan.Sources

Eisai GesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria.Sources

The European Knowledge Centre (now EMEA Knowledge Centre) opens as a European strategic base in Hertfordshire, the United Kingdom.Sources

The Eisai Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D.Sources

Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations.Sources

The Eisai Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India.Sources

The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award.Sources

Eisai Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada.Sources

Production headquarters transforms to a global “Eisai Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing.Sources

Eisai (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China.Sources

Anticancer agent : Halaven : is launched in the United States.Sources

Eisai signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge.Sources

H3 Biomedicine Inc. is established as a research subsidiary in the United States.Sources

The Great East Japan Earthquake strikes.Sources

Eisai rolls out its sixth mid-term plan, “HAYABUSA.”Sources

Eisai Participações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil.Sources

Halaven : is launched in Europe and Japan.Sources

Eisai Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.Sources

Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.Sources

Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).Sources

Antiepileptic agent : Fycompa : is launched in Europe.Sources

Limited Liability Company Eisai is established as a pharmaceutical sales subsidiary in Moscow, Russia.Sources

Eisai co-establishes the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world.Sources

Eisai initiates free of charge provision of diethylcarbamine tablets produced at its Vizag plant in India to WHO for use in the treatment of lymphatic filariasis.Sources

Fycompa : is launched in the United States.Sources

Eisai China Holdings Ltd. is established as a holding company in Suzhou, China.Sources

Anticancer agent : Lenvima : is launched in the United States, Japan and Europe.Sources

Eisai completes acquisition of Chinese generic pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. (new trading name: Eisai (Liaoning) Pharmaceutical Co., Ltd.)Sources

Eisai rolls out its seventh mid-term plan “EWAY2025.”Sources

EA Pharma Co., Ltd. is established as a gastrointestinal specialty pharmaceutical company.Sources

Fycompa : is launched in Japan.Sources

Eisai joins global partnership to address non-communicable diseases.Sources

Eisai pledges continued support for lymphatic filariasis elimination.Sources

Eisai commits funding to the 2nd phase of Global Health Innovative Technology Fund activities.Sources

Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.Sources

Eisai agrees upon a strategic collaboration for : Lenvima : with Merck & Co., Inc., Kenilworth, N.J., U.S.A.Sources

New Suzhou plant in China commences full-scale operation.Sources

Lenvima : (hepatocellular carcinoma) is launched in China.Sources

Eisai Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation.Sources

G2D2 Parkinson’s disease treatment Equfina is launched in Japan.Sources

Fycompa and Halaven are launched in China.Sources

NouKNOW (pronounced “NOH-NOH”), a new tool for self-assessment of brain performance (brain health) is launched in Japan.Sources

DAYVIGO (insomnia treatment) is launched in the United States and Japan.Sources

Eisai Vietnam Co., Ltd. is established as a pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam.Sources

Unlimit Health Limited is established in Shanghai, China.Sources

Eisai rolls out its eighth medium-term business plan 'EWAY Future &Beyond'.Sources

Alzheimer’s disease treatment ADUHELM is granted accelerated approval and launched in the United States.Sources

Eisai enters into a global strategic collaboration agreement with Bristol-Myers Squibb Company for MORAb-202.Sources

Eisai Israel Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel.Sources

Eisai celebrates its 80th anniversary.Sources

Eisai and Biogen amend collaboration agreements on ADUHELM.Sources

Eisai makes Arteryex Inc., a company that plans and develops software, its subsidiary.Sources

Eisai Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa.Sources

Eisai signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases.Sources

Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation.Sources

Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States.Sources

Eisai commits funding to the 3rd phase of Global Health Innovative Technology Fund.Sources

LEQEMBI is granted traditional approval by the FDA.Sources

Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan.Sources

LEQEMBI is launched in Japan.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑